The standard-of-care first-line systemic therapy for metastatic urothelial cancer (mUC) remains platinum-based chemotherapy. Post-platinum options included immune checkpoint inhibitors, fibroblast growth factor receptor (FGFR) inhibitors in patients with FGFR2 or FGFR3 genomic alterations, or antibody-drug conjugates. However, the best sequence of these systemic therapies is unknown. Furthermore, it is unclear if patients with FGFR2 or FGFR3 alterations should receive FGFR inhibitor at an early stage of their disease course.